How to Apply to BioMarin Pharmaceutical

10 min read Last updated April 20, 2026 133 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • BioMarin is a roughly 3,500-person, San Rafael-headquartered rare disease biotech founded in 1997, with a portfolio centered on enzyme replacement therapy, peptide therapeutics, and gene therapy.
  • Voxzogo is the company's growth engine and the single most important product to understand before any interview; Roctavian is the most important commercial cautionary tale.
  • Alexander Hardy, who joined as CEO in late 2023 from Genentech, is actively reshaping BioMarin around portfolio prioritization, financial discipline, and a narrower pipeline focus.
  • The careers site at https://www.biomarin.com/careers/jobs/ runs on TalentBrew. Apply directly there; reject any recruiter who asks you to apply through a different portal.
  • Compensation for mid-level roles in the Bay Area typically lands in the roughly $130,000 to $220,000 base range, with target bonus and an RSU grant on top; senior leadership scales materially higher and is RSU-heavy.
  • BioMarin loses competitive offers most often to Vertex, Genentech, Gilead, Alnylam, and Regeneron, and increasingly to private gene therapy companies offering richer pre-IPO equity.
  • Mission alignment is a real screening axis. Candidates who can articulate why rare disease specifically, in a way that survives scrutiny, materially outperform candidates with stronger generic biotech credentials.
  • Expect on-site interviewing in San Rafael for any senior or technical role; hybrid work exists but is not the cultural default for R&D, manufacturing, and quality functions.
  • Honesty about Roctavian, restructuring, and commercial uncertainty is a feature, not a bug, of the current interview rubric. Candidates who can talk about gene therapy commercial risk maturely have a clear edge.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical (Nasdaq: BMRN) is a San Rafael, California-based biotechnology company founded in 1997 by Christopher Starr and Grant Denison with a then-radical thesis: that ultra-rare genetic diseases, long ignored by the major pharmaceutical industry as commercially unviable, could become the basis of a sustainable specialty business if you committed to the underlying science of enzyme replacement, substrate reduction, and eventually gene therapy. Nearly three decades later, that thesis underpins a company of roughly 3,500 employees with a portfolio that reads like a tour of metabolic and skeletal rare disease: Naglazyme for MPS VI, Vimizim for MPS IVA (Morquio A), Aldurazyme for MPS I, Brineura for CLN2 Batten disease, Kuvan for phenylketonuria (PKU), Palynziq as a more aggressive PKU enzyme substitute therapy, Voxzogo for achondroplasia, and Roctavian as the first FDA-approved gene therapy for severe hemophilia A. The company is structurally a Bay Area biotech, with a sprawling Lindaro campus in San Rafael, manufacturing operations in Marin and Shanbally Ireland, and commercial infrastructure across Europe, Latin America, and Asia. Voxzogo, the daily injectable C-type natriuretic peptide analog for children with achondroplasia, is the current growth engine and has scaled into a multi-billion-dollar product as label expansions have moved into younger patient populations. Roctavian, by contrast, has been one of the most public commercial disappointments in modern gene therapy: priced at roughly $2.9 million per patient and approved with a complex eligibility and durability story, it has booked a small fraction of the revenue analysts originally modeled, and BioMarin has been forced to repeatedly reset expectations and rationalize spend around the program. Alexander Hardy, the former Genentech CEO who took over BioMarin in late 2023, has used that reality as the starting point for an aggressive strategic reset: portfolio prioritization, headcount reductions, sharper R&D focus on Voxzogo lifecycle and a smaller pipeline of skeletal and metabolic candidates, and a more disciplined capital allocation posture. For job seekers, BioMarin in 2026 is a company in transition: still scientifically serious, still genuinely mission-driven around rare disease, but more commercially demanding and less tolerant of legacy roles than the BioMarin of even three years ago.

Application Process

  1. 1
    All open roles are posted at https://www

    All open roles are posted at https://www.biomarin.com/careers/jobs/, which is BioMarin's TalentBrew-powered career site. Treat this as the only legitimate source of openings; BioMarin has publicly warned about recruitment fraud impersonating their hiring brand.

  2. 2
    Create a candidate profile in the TalentBrew portal so you can apply, save searc

    Create a candidate profile in the TalentBrew portal so you can apply, save searches, and set up alerts. Most BioMarin roles allow you to upload a resume and have the parser pre-fill the application; budget a few minutes to clean up the parsed fields, especially employment dates and education.

  3. 3
    Expect a recruiter screen within roughly two weeks of submitting if your backgro

    Expect a recruiter screen within roughly two weeks of submitting if your background maps to the role. Recruiters typically run a 30-minute call covering motivation, compensation expectations, work authorization, location flexibility, and whether you understand the on-site or hybrid expectation for the specific function (R&D, manufacturing, and quality roles are mostly San Rafael, Novato, or Shanbally on-site).

  4. 4
    If you advance, the next stage is usually a hiring manager interview focused on

    If you advance, the next stage is usually a hiring manager interview focused on the specific job scope and your direct experience. For scientific and technical roles this often includes a written or live problem walk-through; for commercial roles it leans on case framing around launch dynamics, payer access, and patient identification.

  5. 5
    Most BioMarin loops include a panel or set of cross-functional interviews, frequ

    Most BioMarin loops include a panel or set of cross-functional interviews, frequently with partners from regulatory, clinical, medical affairs, or manufacturing depending on the function. For senior R&D and gene therapy roles, expect a formal scientific presentation to a panel that may include VPs and the relevant therapeutic area head.

  6. 6
    References, background check, and a written offer typically follow within one to

    References, background check, and a written offer typically follow within one to three weeks of the final round. BioMarin's offers are usually structured as base salary plus annual cash bonus target plus an RSU grant vesting over four years; senior roles often add a sign-on cash component and, occasionally, a sign-on equity grant to offset forfeited stock at a prior employer.

  7. 7
    Onboarding is a structured multi-day program in San Rafael for headquarters hire

    Onboarding is a structured multi-day program in San Rafael for headquarters hires, with mandatory rare disease education modules. New employees should plan to be on-site for the first week even if their long-term role is hybrid.

Resume Tips for BioMarin Pharmaceutical

recommended

Lead with rare disease, orphan drug, or specialty biologics experience if you ha

Lead with rare disease, orphan drug, or specialty biologics experience if you have it. BioMarin recruiters and hiring managers screen heavily for candidates who already understand the operational realities of small patient populations, named patient programs, expanded access, and ultra-rare commercial models. If you've worked at Sanofi Genzyme, Ultragenyx, Alnylam, Vertex rare disease, Sarepta, Travere, or Ionis, name those programs explicitly.

recommended

For scientific and technical roles, surface specific modality experience: enzyme

For scientific and technical roles, surface specific modality experience: enzyme replacement therapy, AAV gene therapy, mRNA, peptide therapeutics, or substrate reduction. BioMarin's pipeline is biologic and gene therapy heavy, and a resume that just says 'biotech R&D' without naming modality, vector, or target class will not survive screening for senior roles.

recommended

If you've supported FDA orphan drug designation, rare pediatric disease designat

If you've supported FDA orphan drug designation, rare pediatric disease designation, breakthrough therapy designation, accelerated approval, or EMA PRIME submissions, list them by program and outcome. Regulatory specificity is one of the strongest signals BioMarin recruiters look for in regulatory, clinical operations, and medical affairs candidates.

recommended

Quantify everything you can defend

Quantify everything you can defend. For commercial roles, that means launch revenue, patient finds, payer wins, and access metrics. For manufacturing, it means batch yield, deviation rates, OEE, or comparability success. For research, it means program advancement (DC to FIH timelines, IND-enabling studies completed, candidates nominated). Vague verbs without numbers read as filler.

recommended

Show that you can work in a regulated environment

Show that you can work in a regulated environment. GxP literacy (GLP, GMP, GCP) is table stakes for nearly every R&D, manufacturing, quality, and clinical role. If you have direct experience with FDA inspections, EMA inspections, or ANVISA registration, call it out by year and outcome.

recommended

Tailor the summary line and the top of the experience section to the specific Bi

Tailor the summary line and the top of the experience section to the specific BioMarin role. The TalentBrew parser and the human reviewer are both reading for direct alignment to the posted requirements, and a generic 'biotech leader' summary loses to a candidate who clearly mirrors the job description's modality and therapeutic area.

recommended

If you are interviewing for a Voxzogo, Roctavian, or pipeline gene therapy role,

If you are interviewing for a Voxzogo, Roctavian, or pipeline gene therapy role, be ready to talk about commercial uncertainty honestly on the resume itself. Highlight launches that did not go to plan and what you learned; BioMarin under Hardy is allergic to candidates who only describe wins.

recommended

Keep formatting ATS-friendly

Keep formatting ATS-friendly. TalentBrew handles single-column resumes with standard headings well, but struggles with multi-column layouts, embedded tables, text inside graphics, and headers/footers that contain critical information. Submit a clean PDF and verify the parsed fields before final submission.

ATS System: TalentBrew

Interview Culture

BioMarin interviews carry the rigor of a Bay Area biotech that has been through both scientific success and very public commercial failure, and that experience is now visible in how the company hires.

Scientific and technical loops are demanding in a Genentech-adjacent way: panels of PhDs and senior scientists who will pull on the threads of your published work or program experience, ask you to defend mechanism-of-action assumptions, and expect you to be honest about what you actually did versus what your team did. For gene therapy and biologics roles, expect questions about AAV capsid choice, transgene design, immunogenicity management, manufacturing comparability, and durability data interpretation; for skeletal and metabolic candidates, expect deep biology questions about underlying disease mechanism, surrogate endpoints, and pediatric considerations. Commercial interviews carry a different but equally clear signature shaped by the Roctavian experience. Hiring managers want to see candidates who understand that a $2.9 million one-time gene therapy is not sold the same way as a $300,000 chronic enzyme replacement, who can articulate why the original Roctavian launch model underperformed without sounding either dismissive or defensive, and who can talk credibly about identifying the maybe one to three thousand globally relevant patients for a given rare disease product. Mission alignment matters more at BioMarin than at most large pharmas; it is genuinely common for interviewers to ask why rare disease specifically, and the strongest answers connect to a personal or family story, a research lineage, or an explicit professional commitment rather than a generic 'I want to help patients.' Culturally, BioMarin under Hardy is a noticeably different company than the BioMarin of the JJ Bienaimé era. Interviewers are more likely to probe for prioritization judgment, comfort with portfolio trade-offs, and willingness to kill projects than they were three years ago. The post-Roctavian commercial reset has flowed into the interview rubric as an explicit preference for candidates who show financial discipline, can navigate ambiguity around pipeline allocation, and are not allergic to the word 'restructuring.' Expect to spend a meaningful amount of time on-site in San Rafael for final-round loops; BioMarin still believes that the way you read a room of scientists, manufacturing leaders, or commercial peers in person is signal that a Zoom panel cannot replicate.

What BioMarin Pharmaceutical Looks For

  • Authentic rare disease orientation. BioMarin can tell the difference between candidates who are intellectually interested in rare disease and candidates who actually understand what it means to support a few hundred patients globally, including the ethical, regulatory, and commercial implications.
  • Modality-specific technical depth. Generalist biotech experience is welcome, but candidates who can speak fluently about enzyme replacement therapy, AAV gene therapy, peptide analogs, or substrate reduction outperform generalists for any technical role.
  • Regulatory sophistication, especially around orphan drug designation, accelerated approval, pediatric label expansion, and global rare disease access pathways including named patient and early access programs.
  • Comfort with commercial uncertainty, especially in gene therapy. The Roctavian experience has made BioMarin allergic to commercial candidates who project false certainty about adoption curves, payer behavior, or patient identification yields.
  • Cross-functional collaboration evidence. Rare disease drug development inherently requires R&D, regulatory, medical affairs, commercial, manufacturing, and patient services to work as one unit; BioMarin filters hard for candidates who can show concrete examples of operating across those boundaries rather than within a single silo.
  • Bay Area biotech operating quality without Bay Area biotech entitlement. The company wants Genentech, Vertex, Gilead, and Alnylam-caliber technical and commercial talent, but will pass on candidates who treat BioMarin as a step down or a fallback option.
  • Owner mentality on cost and prioritization. Under Hardy, BioMarin has restructured, narrowed pipeline scope, and pushed financial discipline into operating teams. Candidates who can cite examples of killing programs, sunsetting initiatives, or making explicit resource trade-offs land better than candidates who only describe expansion.
  • Long-term mission commitment. BioMarin tracks tenure carefully and is wary of candidates whose resume reads as a sequence of two-year rotations through whichever biotech is currently raising the most capital.

Frequently Asked Questions

What does BioMarin actually pay for mid-level roles in the Bay Area?
Mid-level individual contributor base salaries at BioMarin generally land in the roughly $130,000 to $220,000 range depending on function, with scientific, gene therapy, and commercial roles typically clustering toward the upper half of that band. On top of base, expect a target annual cash bonus of roughly 10 to 20 percent and an RSU grant vesting over four years. Total annual cash plus equity for a strong mid-career hire often lands in the $200,000 to $300,000 range, scaling materially higher at director and above. Compensation is competitive with peer Bay Area biotechs but typically trails what Vertex, Genentech, and Gilead offer at the same level.
Is BioMarin a real Bay Area biotech or more of a specialty pharma in disguise?
It is a real Bay Area biotech in operating culture, not a specialty pharma. The Lindaro campus in San Rafael houses meaningful R&D and manufacturing, the company runs its own gene therapy programs end to end including the Shanbally Ireland production site, and the scientific bench is genuinely deep. What separates BioMarin from a research-stage biotech is that it has been profitable, commercial, and on the market for decades, so it carries the operating overhead of a real pharma alongside the science culture of a biotech.
Why do BioMarin offers most often get rejected, and who do they lose to?
The most common loss patterns are to Vertex (especially for cystic fibrosis and rare disease commercial talent), Genentech (for scientific and clinical leadership where the South San Francisco campus and brand still dominate), Gilead (for commercial and medical affairs with HIV or oncology adjacency), Alnylam and Ionis (for RNA-based modality candidates), and increasingly private gene therapy companies offering richer pre-IPO equity. The compensation gap is real at senior levels, but more often the loss is about scope and platform: candidates choose larger pipelines or hotter modalities. BioMarin under Hardy is countering with sharper portfolio focus and clearer career paths rather than chasing the comp ceiling.
How realistic is remote or fully hybrid work at BioMarin?
Less realistic than at most peer biotechs. R&D, manufacturing, quality, and most clinical operations roles are anchored on-site in San Rafael, Novato, or Shanbally Ireland, with limited flexibility. Commercial, medical affairs field roles, and some corporate functions support hybrid or geographically distributed work, and there are remote roles for very specific functions, but the cultural default for headquarters teams is in-office presence multiple days per week. Candidates who require fully remote work should clarify that with the recruiter on the first call rather than assume flexibility.
How seriously should a candidate take the Roctavian commercial story before interviewing?
Very seriously. Roctavian is the inflection point that defines current BioMarin strategy and is also the single most likely topic to come up in a commercial, medical affairs, or strategy interview. Candidates should be able to discuss why a $2.9 million one-time hemophilia A gene therapy has booked a small fraction of original analyst expectations, what that says about gene therapy commercial models more broadly, and how BioMarin appears to be adjusting its organizational and financial posture in response. Show that you can talk about it as a learning opportunity rather than a failure or a victory.
Does BioMarin sponsor work visas, and how strict is the bar?
BioMarin does sponsor H-1B and other employment-based visas for roles where the candidate's background materially exceeds the local talent pool, particularly in scientific, gene therapy, and specialized regulatory functions. The bar is real: for general individual contributor commercial or operations roles, the company typically prefers candidates with existing US work authorization. International candidates are best served by targeting roles where their specific modality or therapeutic area expertise is genuinely scarce, and by being upfront about visa status during the recruiter screen rather than late in the loop.
What is the actual employee experience under Alexander Hardy compared to the prior regime?
Employees describe the post-Hardy company as more disciplined, more commercially focused, and more willing to make hard portfolio calls than the BioMarin of the JJ Bienaimé era. There has been real headcount reduction, real program prioritization, and a sharper expectation that every team can defend its contribution to a tightened pipeline. For high performers in growth areas like Voxzogo, gene therapy, and core skeletal and metabolic R&D, the experience has been positive. For employees in deprioritized programs or roles that overlapped with restructuring, the experience has been considerably harder. Candidates should ask direct questions about team scope, headcount stability, and program runway during interviews.
How important is rare disease background versus general pharma experience?
Important, but not strictly required at every level. For commercial, medical affairs, patient services, and regulatory roles, rare disease or orphan drug experience is heavily preferred and often functionally a requirement at director and above. For scientific, manufacturing, and technical operations roles, modality expertise (gene therapy, biologics, enzyme replacement) often matters more than rare disease specifically. The candidates who lose to general pharma backgrounds tend to be the ones who cannot articulate why rare disease commercial and operating dynamics differ from a typical specialty pharma launch.
What does the interview process actually look like end to end, including timing?
A typical end-to-end loop runs four to eight weeks from initial recruiter contact to written offer. The standard sequence is recruiter screen, hiring manager interview, panel interviews with three to six cross-functional partners (often a mix of virtual and on-site), and for scientific or senior roles a formal presentation. Final on-site rounds in San Rafael are common for senior individual contributor and management roles. References and background check follow the final round, and offers usually arrive within one to three weeks. Senior leadership loops can extend longer, especially when an executive committee sign-off is involved.
Should I apply to BioMarin if I'm coming from a non-rare-disease big pharma background?
Yes, especially for scientific, manufacturing, gene therapy, and global regulatory roles where modality and operating depth matter more than therapeutic area. To compete effectively, invest the time before applying to actually understand the differences between a rare disease commercial model and a typical primary care or specialty launch, study how Voxzogo and Roctavian have been positioned, and adjust your resume and cover letter to mirror the rare disease vocabulary the company uses. Generic big pharma resumes that do not show this translation work tend to lose at the recruiter screen even when the underlying experience is strong.

Open Positions

BioMarin Pharmaceutical currently has 133 open positions.

Check Your Resume Before Applying → View 133 open positions at BioMarin Pharmaceutical

Related Resources

Similar Companies

Sources

  1. BioMarin Pharmaceutical - Official Careers Page —
  2. BioMarin Pharmaceutical - Investor Relations and SEC Filings —
  3. Voxzogo (vosoritide) Prescribing Information - FDA —
  4. Roctavian (valoctocogene roxaparvovec) Prescribing Information - FDA —
  5. BioMarin Pharmaceutical Inc. - Company Profile —
  6. BioMarin Pharmaceutical - Pipeline and Therapies —
  7. BioMarin Pharmaceutical - Newsroom and CEO Transition —
  8. Nasdaq: BMRN - BioMarin Pharmaceutical Stock Profile —